US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
AU658646B2
(en)
|
1991-05-10 |
1995-04-27 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
NZ258697A
(en)
|
1992-11-13 |
1996-03-26 |
Immunex Corp |
Elk-l polypeptide, coding sequence and vector therefor
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
US5612340A
(en)
|
1993-10-01 |
1997-03-18 |
Ciba-Geigy Corporation |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
CA2175215C
(en)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
EP0734389B1
(en)
|
1993-12-17 |
2000-03-29 |
Novartis AG |
Rapamycin derivatives useful as immunosuppressants
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
EP1464706A3
(en)
|
1994-04-15 |
2004-11-03 |
Amgen Inc., |
HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
|
ATE159257T1
(de)
|
1994-05-03 |
1997-11-15 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivate mit antiproliferativer wirkung
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
ES2332984T3
(es)
|
1995-03-30 |
2010-02-16 |
Pfizer Products Inc. |
Derivados de quinazolinas.
|
DK0819129T3
(da)
|
1995-04-03 |
2000-10-23 |
Novartis Ag |
Pyrazolderivater og fremgangsmåde til deres fremstilling
|
US5861510A
(en)
|
1995-04-20 |
1999-01-19 |
Pfizer Inc |
Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
DE69624921T2
(de)
|
1995-06-09 |
2003-09-11 |
Novartis Ag |
Rapamycinderivate
|
DK0836605T3
(da)
|
1995-07-06 |
2002-05-13 |
Novartis Ag |
Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
WO1997027199A1
(en)
|
1996-01-23 |
1997-07-31 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE59710417D1
(de)
|
1996-03-15 |
2003-08-14 |
Novartis Ag |
N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
|
NZ332119A
(en)
|
1996-04-12 |
2001-08-31 |
Warner Lambert Co |
Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
ATE308527T1
(de)
|
1996-06-24 |
2005-11-15 |
Pfizer |
Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19430A
(id)
|
1996-07-13 |
1998-07-09 |
Glaxo Group Ltd |
Senyawa senyawa heterosiklik
|
PT912559E
(pt)
|
1996-07-13 |
2003-03-31 |
Glaxo Group Ltd |
Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
|
TR199900066T2
(xx)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
|
DK0920505T3
(da)
|
1996-08-16 |
2008-09-08 |
Schering Corp |
Pattedyrcelleoverfladeantigener og tilhörende reagenser
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
JP4242928B2
(ja)
|
1996-08-23 |
2009-03-25 |
ノバルティス アクチエンゲゼルシャフト |
置換ピロロピリミジンおよびその製造方法
|
CA2264284A1
(en)
|
1996-08-23 |
1998-02-26 |
Ralph P. Robinson |
Arylsulfonylamino hydroxamic acid derivatives
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
AU720135B2
(en)
|
1996-10-02 |
2000-05-25 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
PT950059E
(pt)
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
PT977733E
(pt)
|
1997-02-03 |
2003-12-31 |
Pfizer Prod Inc |
Derivados de acido arilsulfonilamino-hidroxamico
|
EP0964864B1
(en)
|
1997-02-05 |
2008-04-09 |
Warner-Lambert Company LLC |
Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
AU722784B2
(en)
|
1997-02-11 |
2000-08-10 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
IL134300A
(en)
|
1997-08-08 |
2004-07-25 |
Pfizer Prod Inc |
Derivatives of aryloxyacrylylsulfonaminoaminoxamic acid derivatives, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of arthritis, cancer and other diseases characterized by the activity of metalloproteinase-13 of matrix
|
EP1025228A4
(en)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
EP1053321A1
(en)
|
1998-02-09 |
2000-11-22 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
AU756838B2
(en)
|
1998-03-04 |
2003-01-23 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2336848A1
(en)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
EP1109555A4
(en)
|
1998-08-31 |
2001-11-21 |
Merck & Co Inc |
NEW ANGIOGENIC INHIBITORS
|
PT1004578E
(pt)
|
1998-11-05 |
2004-06-30 |
Pfizer Prod Inc |
Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
|
WO2000059509A1
(en)
|
1999-03-30 |
2000-10-12 |
Novartis Ag |
Phthalazine derivatives for treating inflammatory diseases
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
CA2374851A1
(en)
|
1999-06-07 |
2000-12-14 |
Immunex Corporation |
Tek antagonists
|
IL147442A0
(en)
|
1999-07-12 |
2002-08-14 |
Genentech Inc |
Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
|
AU783158B2
(en)
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
SK287401B6
(sk)
|
1999-11-05 |
2010-09-07 |
Astrazeneca Ab |
Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
|
PT1233943E
(pt)
|
1999-11-24 |
2011-09-01 |
Sugen Inc |
Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
ATE373078T1
(de)
|
2000-02-24 |
2007-09-15 |
Xcyte Therapies Inc |
Gleichzeitige stimulation und konzentration von zellen
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
IL151032A0
(en)
|
2000-02-25 |
2003-04-10 |
Immunex Corp |
Integrin antagonists
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
DK2311825T3
(en)
|
2000-12-21 |
2016-01-18 |
Novartis Ag |
Pyrimidinamines AS ANGIOGENESEMODULATORER
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
EP1646634B1
(en)
|
2003-07-08 |
2008-11-12 |
Novartis AG |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
EP1648900A4
(en)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
PHOSPHORUS MACROCYCLES
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
SG145749A1
(en)
|
2003-08-15 |
2008-09-29 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
WO2005094314A2
(en)
|
2004-03-26 |
2005-10-13 |
The Burnham Institute |
Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
RS51362B
(en)
|
2004-08-26 |
2011-02-28 |
Pfizer Inc. |
ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
|
US7666901B2
(en)
|
2004-10-13 |
2010-02-23 |
Wyeth |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
US7745451B2
(en)
|
2005-05-04 |
2010-06-29 |
Renovis, Inc. |
Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
|
CA2607147C
(en)
|
2005-05-09 |
2018-07-17 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
MX2008001041A
(es)
|
2005-09-20 |
2008-03-19 |
Pfizer Prod Inc |
Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa.
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
US8987474B2
(en)
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
EP2518074B1
(en)
|
2006-12-07 |
2015-07-22 |
F.Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
MX338504B
(es)
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
NZ590667A
(en)
|
2008-07-02 |
2013-01-25 |
Emergent Product Dev Seattle |
Tgf-b antagonist multi-target binding proteins
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
NZ598262A
(en)
|
2009-08-17 |
2014-05-30 |
Sloan Kettering Inst Cancer |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2011090762A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
US9096600B2
(en)
|
2010-12-20 |
2015-08-04 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
US8623885B2
(en)
|
2011-03-23 |
2014-01-07 |
Amgen Inc. |
Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
WO2014015291A1
(en)
|
2012-07-20 |
2014-01-23 |
Han-Jie Zhou |
FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
|
US20150352131A1
(en)
|
2013-01-16 |
2015-12-10 |
Rhode Island Hospital |
Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
WO2014176488A1
(en)
|
2013-04-26 |
2014-10-30 |
Indiana University Research & Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
|
EP3016652A4
(en)
|
2013-07-03 |
2017-03-08 |
Indiana University Research and Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
US10093646B2
(en)
|
2014-01-17 |
2018-10-09 |
Novartis Ag |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
CN105418632B
(zh)
|
2014-09-19 |
2020-02-21 |
上海创诺医药集团有限公司 |
噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
|
WO2016077793A1
(en)
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
PL3244891T3
(pl)
|
2015-01-16 |
2022-12-27 |
The General Hospital Corporation |
Związki poprawiające splicing mRNA
|
US20180121597A1
(en)
|
2015-05-22 |
2018-05-03 |
Allosta Pharmaceuticals |
Methods to Prepare and Employ Binding Site Models for Modulation of Phosphatase Activity and Selectivity Determination
|
US10494332B2
(en)
|
2015-06-01 |
2019-12-03 |
Indiana University Research And Technology Corporation |
Protein tyrosine phosphatases or SHP2 inhibitors and uses thereof
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
EP3310771B1
(en)
|
2015-06-19 |
2020-07-22 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
DK3325490T3
(da)
|
2015-07-23 |
2020-02-03 |
Takeda Pharmaceuticals Co |
1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
US11008372B2
(en)
|
2015-11-07 |
2021-05-18 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
WO2017210134A1
(en)
|
2016-05-31 |
2017-12-07 |
Board Of Regents, University Of Texas System |
Heterocyclic inhibitors of ptpn11
|
CA3026784A1
(en)
|
2016-06-07 |
2017-12-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic pyrazine derivatives useful as shp2 inhibitors
|
MX2019000548A
(es)
|
2016-07-12 |
2019-10-30 |
Revolution Medicines Inc |
3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
|
EP3515916B1
(en)
|
2016-09-22 |
2023-06-07 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
TW201819386A
(zh)
|
2016-10-24 |
2018-06-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
CN110167928A
(zh)
|
2016-12-22 |
2019-08-23 |
勃林格殷格翰国际有限公司 |
作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
RU2769132C2
(ru)
|
2017-01-10 |
2022-03-28 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
|
MX2019008695A
(es)
|
2017-01-23 |
2019-09-11 |
Revolution Medicines Inc |
Compuestos biciclicos como inhibidores alostericos de shp2.
|
CA3051054A1
(en)
|
2017-01-23 |
2018-07-26 |
Revolution Medicines, Inc. |
Pyridine compounds as allosteric shp2 inhibitors
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
CA3056970A1
(en)
|
2017-03-21 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
WO2018172984A1
(en)
|
2017-03-23 |
2018-09-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
IL270333B2
(en)
|
2017-05-02 |
2023-11-01 |
Revolution Medicines Inc |
Rapamycin derivatives as MTOR tracers
|
EP3630770A1
(en)
|
2017-05-26 |
2020-04-08 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
WO2019051084A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS
|
US11701354B2
(en)
|
2017-09-29 |
2023-07-18 |
D. E. Shaw Research, Llc |
Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
|
KR20200111163A
(ko)
*
|
2017-12-21 |
2020-09-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
|
WO2019152454A1
(en)
|
2018-01-30 |
2019-08-08 |
Research Development Foundation |
Shp2 inhibitors and methods of use thereof
|
EP3753941B1
(en)
|
2018-02-13 |
2024-05-01 |
Shanghai Blueray Biopharma Co., Ltd. |
Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
|
US20200392161A1
(en)
|
2018-02-21 |
2020-12-17 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
KR20200127005A
(ko)
|
2018-03-02 |
2020-11-09 |
오쓰까 세이야꾸 가부시키가이샤 |
약제학적 화합물
|
RU2020133727A
(ru)
|
2018-03-21 |
2022-04-21 |
Сучжоу Пухе Биофарма Ко., Лтд. |
Ингибиторы shp2 и их применение
|
WO2019183364A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
CA3094690A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
CA3096535A1
(en)
|
2018-04-10 |
2019-10-17 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
|
WO2019201848A1
(en)
|
2018-04-18 |
2019-10-24 |
Bayer Pharma Aktiengesellschaft |
2-methyl-aza-quinazolines
|
WO2019212991A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
JP7358387B2
(ja)
|
2018-05-01 |
2023-10-10 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc40-、c28-およびc-32-連結ラパマイシン類似体
|
EP3787627A4
(en)
|
2018-05-02 |
2021-12-01 |
Navire Pharma, Inc. |
SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11
|
US20210230300A1
(en)
|
2018-06-04 |
2021-07-29 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
JP7174143B2
(ja)
|
2018-07-24 |
2022-11-17 |
大鵬薬品工業株式会社 |
Shp2活性を阻害するヘテロ二環性化合物
|
WO2020033286A1
(en)
|
2018-08-06 |
2020-02-13 |
Purdue Research Foundation |
Novel sesquiterpenoid analogs
|
AU2019319971A1
(en)
|
2018-08-10 |
2021-03-25 |
Navire Pharma, Inc. |
6-(4-amino-3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
|
MX2021003158A
(es)
|
2018-09-18 |
2021-07-16 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
WO2020076723A1
(en)
|
2018-10-08 |
2020-04-16 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions for use in treating cancer
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
US20210380582A1
(en)
|
2018-10-17 |
2021-12-09 |
Array Biopharma Inc. |
Protein tyrosine phosphatase inhibitors
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
CN115315424A
(zh)
|
2019-10-15 |
2022-11-08 |
拜耳公司 |
2-甲基-氮杂-喹唑啉
|
MX2022005525A
(es)
*
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|